Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR).


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
12 05 2023
Historique:
medline: 15 5 2023
pubmed: 13 5 2023
entrez: 12 5 2023
Statut: epublish

Résumé

Transradial access (TRA) has rapidly emerged as the preferred vascular access site for coronary angiography and percutaneous coronary intervention. Radial artery occlusion (RAO) remains as an important complication of TRA as it precludes future ipsilateral transradial procedures. While intraprocedural anticoagulation has been studied extensively, the definitive role of postprocedural anticoagulation has not yet been established. The Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion trial is a multicentre, prospective, randomised, open-label, blinded-endpoint design study investigating the efficacy and safety of rivaroxaban to reduce the incidence of RAO. Eligible patients will undergo randomisation to receive either rivaroxaban 15 mg once daily for 7 days or to no additional postprocedural anticoagulation. Doppler ultrasound to assess radial artery patency will be performed at 30 days. The study protocol has been approved by the Ottawa Health Science Network Research Ethics Board (approval number 20180319-01H). The study results will be disseminated via conference presentations and peer-reviewed publications. NCT03630055.

Identifiants

pubmed: 37173116
pii: bmjopen-2022-070720
doi: 10.1136/bmjopen-2022-070720
pmc: PMC10186464
doi:

Substances chimiques

Rivaroxaban 9NDF7JZ4M3
Anticoagulants 0

Banques de données

ClinicalTrials.gov
['NCT03630055']

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e070720

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Vasc Med. 2012 Oct;17(5):352-61
pubmed: 22814998
Circ Cardiovasc Interv. 2012 Feb 1;5(1):127-33
pubmed: 22338002
Circ Cardiovasc Interv. 2018 Sep;11(9):e000035
pubmed: 30354598
Circ Cardiovasc Interv. 2022 Apr;15(4):e011555
pubmed: 35317614
J Am Heart Assoc. 2016 Jan 25;5(1):
pubmed: 26811162
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
N Engl J Med. 2013 Aug 29;369(9):799-808
pubmed: 23808982
Eur Heart J Acute Cardiovasc Care. 2019 Sep;8(6):510-519
pubmed: 31237158
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
N Engl J Med. 2009 Dec 10;361(24):2342-52
pubmed: 19966341
JACC Cardiovasc Interv. 2019 Nov 25;12(22):2235-2246
pubmed: 31753298
Catheter Cardiovasc Interv. 2002 Oct;57(2):172-6
pubmed: 12357515
Catheter Cardiovasc Interv. 2016 Apr;87(5):868-74
pubmed: 26269451
Catheter Cardiovasc Interv. 2001 Oct;54(2):204-8
pubmed: 11590685
Acta Cardiol. 2017 Jun;72(3):318-327
pubmed: 28636520
J Invasive Cardiol. 2015 Feb;27(2):106-12
pubmed: 25661763
N Engl J Med. 2016 Dec 22;375(25):2423-2434
pubmed: 27959713
Am J Cardiol. 2009 Oct 15;104(8):1083-5
pubmed: 19801029
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Front Cardiovasc Med. 2023 Apr 21;10:1160459
pubmed: 37153470
N Engl J Med. 2013 Oct 10;369(15):1406-15
pubmed: 23991658
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Catheter Cardiovasc Interv. 2012 Jan 1;79(1):78-81
pubmed: 21584923
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Catheter Cardiovasc Interv. 2014 Feb;83(2):228-36
pubmed: 24123781
J Am Heart Assoc. 2017 Aug 23;6(8):
pubmed: 28838915
Can J Cardiol. 2014 Feb;30(2):211-6
pubmed: 24461923
JACC Cardiovasc Interv. 2018 Nov 26;11(22):2241-2250
pubmed: 30391389
J Invasive Cardiol. 2007 Dec;19(12):541-4
pubmed: 18180525
Am Heart J. 2013 Mar;165(3):325-31
pubmed: 23453100
Circ Cardiovasc Interv. 2021 Mar;14(3):e009994
pubmed: 33685220
Catheter Cardiovasc Interv. 2008 Sep 1;72(3):335-340
pubmed: 18726956
EuroIntervention. 2014 Nov;10(7):824-32
pubmed: 24472679
JACC Cardiovasc Interv. 2016 Jul 25;9(14):1419-34
pubmed: 27372195
Eur Heart J. 2010 Jul;31(13):1608-15
pubmed: 20413398
N Engl J Med. 2017 Oct 19;377(16):1513-1524
pubmed: 28844193
Catheter Cardiovasc Interv. 2007 Aug 1;70(2):185-9
pubmed: 17203470
Am J Cardiol. 2016 Aug 15;118(4):482-8
pubmed: 27378143
N Engl J Med. 2012 Apr 5;366(14):1287-97
pubmed: 22449293
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Can J Cardiol. 2020 Dec;36(12):1847-1948
pubmed: 33191198
EuroIntervention. 2017 Aug 4;13(5):e549-e556
pubmed: 28218605
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041

Auteurs

Pietro Di Santo (P)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
Department of Critical Care, University of Ottawa, Ottawa, Ontario, Canada.

Omar Abdel-Razek (O)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Richard Jung (R)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Simon Parlow (S)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Anthony Poulin (A)

Division of Cardiology, Quebec Heart and Lung Institute, Quebec, Québec, Canada.

Jordan Bernick (J)

Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Baylie Morgan (B)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Lisa Robinson (L)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Hannah Feagan (H)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Jilliane Wade (J)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Cheng Yee Goh (CY)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Kuljit Singh (K)

Department of Cardiology, Gold Coast University Hospital, Southport, Queensland, Australia.

Michael Froeschl (M)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Marino Labinaz (M)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Dean A Fergusson (DA)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Doug Coyle (D)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

Kwadwo Kyeremanteng (K)

Department of Critical Care, University of Ottawa, Ottawa, Ontario, Canada.

Joseph Abunassar (J)

Division of Cardiology, Queen's University, Kingston, Ontario, Canada.

George A Wells (GA)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Trevor Simard (T)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Benjamin Hibbert (B)

CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada bhibbert@ottawaheart.ca.
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH